Behandling af follikulær lymfom med stor tumorbyrde i kombination med passende induktionskemoterapi, såsom CHOP-lignende regimer.

Treatment of high tumour burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen.

Som vedligeholdelsesbehandling hos patienter, som har opnået objektiv remission (mere end 50% reduktion i myeloid protein) efter initial induktionskemoterapi.

As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.

Myelomatose:Som vedligeholdelsesbehandling hos patienter, som har opnået objektiv remission (mere end 50% reduktion i myeloid protein) efter initial induktionskemoterapi.

162 major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.Multiple Myeloma:As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.

CCR bestod af BSC alene (n = 105), lavdosis cytarabin plus BSC (n = 49) eller standard induktionskemoterapi plus BSC (n = 25).
http://www.emea.europa.eu/

CCR consisted of BSC alone (n = 105), low-dose cytarabine plus BSC (n = 49) or standard induction chemotherapy plus BSC (n = 25).
http://www.emea.europa.eu/

Overlevelsesgevinsten ved Vidaza var konsekvent, uanset hvilken CCR- behandlingsoption (BSC alene, lavdosis cytarabin plus BSC eller standard induktionskemoterapi plus BSC), der blev anvendt i kontrolgruppen.
http://www.emea.europa.eu/

The survival benefits of Vidaza were consistent regardless of the CCR treatment option (BSC alone, low-dose cytarabine plus BSC or standard induction chemotherapy plus BSC) utilised in the control arm.
http://www.emea.europa.eu/

Behandling med filgrastim reducerer i signifikant grad varigheden af febril neutropeni, brug af antibiotika samt hospitalsindlæggelse efter induktionskemoterapi mod akut myeloid leukæmi eller myeoablativ behandling efterfulgt af knoglemarvstransplantation.
http://www.emea.europa.eu/

Treatment with filgrastim significantly reduces the duration of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation.
http://www.emea.europa.eu/

Ligeledes medfører behandling med filgrastim signifikant reduktion af varigheden af febril neutropeni, brug af antibiotika og hospitalsindlæggelse efter behandling af akut myeloid leukæmi med induktionskemoterapi eller myeloablativ terapi efterfulgt af knoglemarvstransplantation.
http://www.emea.europa.eu/

Treatment with filgrastim significantly reduces the duration of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation.
http://www.emea.europa.eu/

Hos patienter, som er i plateaufase (mere end 50% reduktion af myelom-protein) efter initial induktionskemoterapi, kan interferon alfa-2b gives som monoterapi, subkutant i en dosering på 3 millioner IE/m2 tre gange om ugen (hver anden dag) .

In patients who are in the plateau phase (more than 50% reduction of myeloma protein) following initial induction chemotherapy, interferon alfa-2b may be administered as monotherapy, subcutaneously, at a dose of 3 million IU/m2 three times a week (every other day) .

Hos patienter, som er i plateaufase (mere end 50% reduktion af myelom- protein) efter initial induktionskemoterapi, kan interferon alfa- 2b gives som monoterapi, subkutant i en dosering på 3 millioner IE/ m2 tre gange om ugen (hver anden dag).
http://www.emea.europa.eu/

In patients who are in the plateau phase (more than 50% reduction of myeloma protein) following initial induction chemotherapy, interferon alfa-2b may be administered as monotherapy, subcutaneously, at a dose of 3 million IU/m2 three times a week (every other day).
http://www.emea.europa.eu/